People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocunexus Therapeutics, Inc. | — | Biotechnology | Series B | $53.2M | $292.6M | 2011 |
Bradford Duft at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bradford Duft on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| James Blair | 1 | 8 |
| Brian Levy | 1 | 8 |
| David Pool | 1 | 4 |
| Inna Martin Eitan | 1 | 2 |
| Geoff Brooke | 1 | 2 |
| Howard "Ted" Greene | 1 | 1 |
| Howard Greene, Jr. | 1 | 1 |
| Mikhail Getman | 1 | 1 |
| Pavel Rodyukov | 1 | 1 |
| Anton Gopka | 1 | 1 |
| James Mervis | 1 | 1 |
| Colin Green | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.